Dr. Judah Folkman
Keynote Speaker
Children’s Hospital; Director, Vascular Biology Program Harvard Medical School; Andrus Professor of Pediatric Surgery and Professor of Cell Biology
Dr. Folkman is the author of 389 original peer-reviewed papers and 106 book chapters and monographs. He also holds honorary degrees from fifteen universities and is the recipient of numerous national and international awards. He has been elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the American Philosophical Society, and the Institute of Medicine of the National Academy of Sciences.
In addition to his distinguished accomplishments in research, Dr. Folkman has served as a surgeon and teacher. He began his career as an instructor in surgery for Harvard’s Surgical Service at Boston City Hospital Boston, was promoted to professor of surgery at Harvard Medical School, and became the Julia Dyckman Andrus Professor of Pediatric Surgery in 1968. From 1967 he served as surgeon-in-chief at the Children’s Hospital Boston for fourteen years. Dr. Folkman is also a professor of cell biology at Harvard Medical School and is currently director of the Vascular Biology Program at Children’s Hospital Boston.

Keith F. Batchelder, MD
CEO, Genomic Healthcare Strategies
Dr. Batchelder has been a consultant for a several health care companies including GenData, a new nonprofit corporation created by the State of Utah, the University of Utah, and the Huntsman Cancer Foundation, where he was the architect of a strategy to leverage the Utah Population Database (genotypic and phenotypic information from founder families) in clinical trials and drug discovery; and Scientia, an oncology phenotype company working in a unique alliance with the National Comprehensive Cancer Network, where he set up a system to collect new genomic, gene expression profiling and proteomics data in cancer. He has also been an officer in several health-care organizations.

David Resnick, JD
Partner, Nixon Peabody LLP
David Resnick focuses his practice on medical technology and biotechnology, including patent prosecution, patent interferences, transaction matters, and associated client counseling. He has extensive experience in prosecuting applications for major U.S. research institutions and domestic and international corporations. Mr. Resnick has developed a particular focus in the areas of pharmacogenomics, proteomics, and disease biomarkers, and their application in the evolving field of personlized medicine.
Mr. Resnick has assisted in representing major U.S. research institutions, U.S. companies, and foreign corporations, handling interferences before the U.S. Patent and Trademark Office that have involved a large number of complex technical areas. He has also assisted clients by evaluating their intellectual property portfolios as well as the intellectual property held by competitors or potential acquisitions or partners. In connection with these activities, he has been involved with due diligence analyses and has prepared infringement and validity opinions.
Mr. Resnick has lectured to the Association of University and Technology Managers, Inc. (AUTM), and he has written articles on patent prosecution practice and technology issues for Nature Biotechnology and other publications.

Edward Abrahams, PhD
Executive Director, Personalized Medicine Coalition
Edward Abrahams, executive director of the Personalized Medicine Coalition, a nonprofit educational and advocacy group representing diverse members with a interest in advancing medical progress through the adoption of personalized medicine concepts and products, brings extensive experience in industry, academia, and government to the position. As former executive director of the Pennsylvania Biotechnology Association, Dr. Abrahams managed all aspects of the Association, including public advocacy, media relations, and educational programs, tripling its size and revenues in three years. He also spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in that state.
Previously, Mr. Abrahams had been assistant vice president for Federal Relations at the University of Pennsylvania, and also held a senior administrative position at Brown University. Before becoming a university administrator, Dr. Abrahams worked seven years for the United States Congress, including as a legislative assistant to Senator Lloyd Bentsen and as an economist for the Joint Economic Committee under the chairmanship of Congressman Lee Hamilton.
In addition to articles in both popular and professional journals, he is the author of The Lyrical Left: Randolph Bourne, Alfred Stieglitz and the Origins of Cultural Radicalism in America.

Mara Aspinall
President, Genzyme Genetics
Mara Aspinall is the president of Genzyme Genetics, a leading worldwide provider of testing and consultative services. Genzyme Genetics is a division of Genzyme Corporation, one of the world’s largest biotechnology firms.
From its roots twenty years ago, Genzyme Genetics has established itself as one of the industry’s foremost independent testing labs, performing almost one million tests annually and employing the nation’s largest network of board-certified genetic counselors. Genzyme Genetics has nine laboratories across the U.S., operations in Japan, and is a leader in prenatal, reproductive, and cancer testing. Over the past four years, Genzyme Genetics has achieved record growth in sales and profits while setting the quality standard within the testing industry. Most recently, Genzyme Genetics acquired the assets of IMPATH, Inc., one of the nation’s largest cancer testing companies, making Genzyme Genetics one of the top five commercial laboratories in the U.S. Harold J.

Harold J. Burstein, MD, PhD
Assistant Professor of Medicine, Harvard Medical School
Clinical Professor Dana-Farber Cancer Institute
Dr. Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master’s degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. In 1999, he joined the staff of DFCI and Brigham and Women’s Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.
In the Breast Oncology Center, clinical trials help define new treatment options for women with early-stage and advanced breast cancer. These trials use the scientific resources at DF/HCC to translate clinical observations into well described biological phenomena.

Tom Delbanco, MD
Richard and Florence Koplow–James Tullis Professor of General Medicine and Primary Care, Harvard Medical School
Tom Delbanco, MD, is the Richard and Florence Koplow–James Tullis Professor of General Medicine and Primary Care, Harvard Medical School. Until 2002, he was chief of the General Medicine and Primary Care division of Beth Israel Deaconess Medical Center, a unit he created and led for more than thirty years. He was the founding chair of the Picker Institutes in the USA and Europe. Dr. Delbanco came to Boston and created one of the first primary care practice and teaching programs at an academic health center. Today, Healthcare Associates provides for more than ninety thousand patient visits annually and serves four hundred patients with HIV infection.
One of five founders of the Society of General Internal Medicine, an organization of three thousand physicians and social scientists in academic general internal medicine, he served as its president in 1986.

Robert Jevon
Partner, Boston Millenia Partners
Robert Jevon is a partner at Boston Millennia, a diversified venture capital fund with $700 million under management. Rob focuses on investments in health care and life sciences. His previous experience includes Watch Hill Corporation, a Boston-based private investment firm, and Bolt Beranek and Newman, where he served as controller of the Communications Division and CFO of the airline reservations subsidiary located in Copenhagen. Earlier he held financial management positions at General Electric and Puritan Life Insurance Company.
Rob currently sits on the boards of Galt Associates, Athenix Corporation, Novalar, and Protein Forest. Previously he had management responsibility for Proteome (acquired by Incyte Genomics, Inc., HotJobs, eMed, Netifice Corporation, and iParty.
Mr. Jevon is a graduate of Haverford College with an AB in economics and has an MBA from the Amos Tuck School at Dartmouth College.

David Margulies, MD
CEO, Correlagen, Inc.
David Margulies is a cofounder and CEO of Correlagen Diagnostics, Inc., a Cambridge-based company that develops and commercializes molecular diagnostic testing services.
Dr. Margulies is Board-certified in internal medicine (Harvard Medical School, 1977) and has served on the faculties of Columbia College of Physicians and Surgeons (1979–1986) and Harvard Medical School (1986–1990) and the administration of Children’s Hospital (Boston) as CIO (1986–1990) and vice president, medical affairs.
His commercial work began in the late 1970s and was initially focused on commercial health care knowledge management and clinical process automation software. He and a partner founded BRS/Medical (later, BRS/Saunders), the organization that developed full text searching of biomedical information (1979–1983).
In 1996, he cofounded CareInsite (now, post-merger, WebMD) to bring health care services to the Web. He left at the time of the merger and went on to found Correlagen, whose diagnostic services enable physicians and their patients to understand the clinical significance of variants in “Genes That Matter™.” Correlagen develops highly automated diagnostic testing services by designing DNA sequence-based assays that analyze the clinical meaning of sequence variants and yield instructive, accurate, revisable reports for physicians and their patients.

Donna Marino
Principal, Genomic Healthcare Strategies
Ms. Marino has created and implemented successful marketing strategies to grow major brands for Unilever, Grand Metropolitan, and Lederle Laboratories. She translates this Fortune 100 experience when advising existing and emerging enterprises in medical and consumer health businesses.
As principal of Marino LLC, Ms. Marino has been engaged in strategic planning, sales, marketing, management recruitment, and operations in the field of diagnostic testing. She has worked for and with consumer, clinical and genomic diagnostic companies including:
Orchid BioSciences, for whom she developed a consumer market entry plan for a genomic diagnostic test with modest up-front investment on a relatively short breakeven schedule.
Ms. Marino was previously the vice president of nutraceuticals at Lipton, a division of Unilever. She helped Unilever devise its global nutraceuticals strategy and led nutraceuticals innovation in the U.S., developing a line of functional foods leveraging Unilever’s core competencies across their foods, personal care, and diagnostic businesses. Ms. Marino initiated a strategic alliance with a major ingredient supplier for a new dietary component with an FDA petition for GRAS status and built strong relationships within the nutrition science community and among women’s health groups. She joined the company as vice president and general manager of a Lipton foods line, where she was responsible for the turnaround of a major business unit within the company.

Peter Miller
Principal, Genomic Healthcare Strategies
Peter Miller is an experienced entrepreneur, manager, innovator, coach, strategist, and consultant. He has spent his career helping build entrepreneurial companies.
Mr. Miller was a founding member, and later vice president, COO, and board member, of Abt Associates Inc., now a $180-million firm working in fields such as health care research and policy, clinical trials, and survey research. At Abt he ran all day-to-day operations, sales and marketing, service delivery, and planning.
He has helped build a number of companies in software and professional services and grow them to the acquisition stage. These include Waterfield Technology Group and SNAP Software, where he was a board member and COO. SNAP was sold to Dun & Bradstreet and Waterfield to Whitman Hart.
Mr. Miller has worked on seven successful money-raising ventures and has been involved in M/A activities on both “buy” and “sell” sides. He has been a licensed (NASD) broker/dealer.
He is the former board chairman of the International MIT Enterprise Forum, a past board member of the MIT Alumni Association, and currently serves as codirector of the MIT Venture Mentoring Service.

Lita Nelsen, MS
Director, Technology Licensing Office, MIT
Lita Nelsen is the director of the Technology Licensing Office at the Massachusetts Institute of Technology, where she has been since 1986. This office manages over four hundred new inventions per year from MIT, the Whitehead Institute, and Lincoln Laboratory. Typically, they negotiate over one hundred licenses and start up over twenty new companies per year.
Ms. Nelsen earned B.S. and M.S. degrees in chemical engineering from MIT and an M.S. in management from MIT as a Sloan Fellow.
Prior to joining the MIT Technology Licensing Office, Ms. Nelsen spent twenty years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology, at such companies as Amicon, Millipore, Arthur D. Little, Inc., and Applied Biotechnology.
Ms. Nelsen was the 1992 president of the Association of University Technology Managers and serves on the board the Mount Auburn Hospital, and the Scientific Advisory Board of the Children’s Hospital Oakland Research Foundation. She serves as the intellectual property advisor to the International AIDS Vaccine Initiative and is a founding and current board member of the Center for Management of Intellectual Property in Health Research.

Phil Reilly, MD, JD
CEO, InterLeukin Genetics
Philip R. Reilly, MD, JD, has been CEO of Interleukin Genetics, Inc., a biotechnology company that focuses on developing predictive genetic tests, since December 1999. Prior to joining Interleukin Genetics, he was for ten years the executive director of the Eunice Kennedy Shriver Center for Mental Retardation, Inc., an NIH funded research institute in Waltham, Massachusetts. He has held academic appointments as assistant professor at Harvard Medical School (1990–98), adjunct professor at Brandeis University (1995–99) and assistant professor at Tufts University School of Medicine (1998–2001). He has twice served as president (2000 and 2003) of the American Society of Law, Medicine, and Ethics. From 1994 to 1997 he was a member of the Board of Directors of the American Society of Human Genetics.
Dr. Reilly has served on many national committees chartered to study public policy issues raised by advances in genetics. From 1998 to 2000 he served on the National Commission on the Future of DNA Evidence for Attorney General Janet Reno.
Dr. Reilly has frequently appeared in the national media to comment on advances in genetics. He is a sought after public speaker who has given hundreds of invited lectures. He has written more than one hundred scholarly articles and five books. One, Abraham Lincoln’s DNA and Other Adventures in Genetics (Cold Spring Harbor Laboratory Press), was chosen by the city of Ann Arbor as its book of the year for 2003. Dr. Reilly’s new book, Is It In Your Genes?, will be published in the spring of 2004.
He earned his BA at Cornell University, his JD from Columbia University, and his MD from Yale University. He is board certified in internal medicine and clinical genetics.

Victoria Richon, PhD
Senior Director, Cancer Biology and Therapeutics
Dr. Victoria Richon joined Merck Research Laboratories, Boston, in 2004 as senior director of cancer biology and therapeutics following the acquisition of Aton Pharma, Inc. Dr. Richon was a cofounder and executive director of Biology of Aton. She was a leading member of the scientific group that discovered Aton’s histone deacetylase inhibitors while at Memorial Sloan-Kettering Cancer Center from 1989 until 2002. She did postdoctoral research in the laboratory of Drs. Paul Marks and Richard Rifkind at Memorial Sloan-Kettering Cancer Center from 1986 until 1989. Dr. Richon received her PhD in biochemistry at the University of Nebraska in 1986 and her BA in chemistry from the University of Vermont in 1981.

Barry G. Zallen, MD
Medical Director, Blue Cross Blue Shield of Massachusetts
Barry G. Zallen earned his AB in biology at Brown University and his MD at Northwestern University Medical School. Dr. Zallen did his residency training in pediatrics at Boston Floating Hospital at New England Medical Center and at Children’s Hospital in Boston. He also completed a fellowship in general and developmental pediatrics at Children’s Hospital.
Following a few years on the faculty at the University of Colorado School of Medicine, Dr. Zallen joined Harvard Community Health Plan (now Harvard Vanguard Medical Associates) as a pediatrician. In 1991, Dr. Zallen led the testing and implementation of IntraPractice Systems (IPS) at HCHP’s Burlington Health Center. IPS included a clinical information system and a home component through which patients could access health information and medical advice based on their symptoms. In 1997, Dr. Zallen led the first implementation of EpicCare at HCHP.
Dr. Zallen’s clinical interests include developmental and behavioral pediatrics, and genomics. His responsibilities at BCBSMA include working with physicians across Massachusetts, leading the development of evidence-based medicine pay-for-performance programs and other incentive programs, and leading BCBSMA’s efforts to bring e-health technologies to providers and patients across the state.